Mitochondria treatment for refractory polymyositis or dermatomyositis
Part of Bones, joints & muscles, Brain & nervous system, Skin clinical trials.
This study tests an experimental treatment made from mitochondria (the energy centers of cells) for people with polymyositis or dermatomyositis that hasn't improved with standard treatments. It aims to see if the treatment is safe and can help reduce muscle weakness and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with polymyositis or dermatomyositis (muscle inflammation) and have symptoms like muscle weakness that has not improved with usual treatments.
- Your doctor has confirmed active disease through tests like blood tests (creatine kinase) or muscle activity tests.
- You are currently taking steroids or other immune-suppressing medicines but they aren't working well enough, or you had to stop due to side effects.
- You are willing to keep the same level of physical therapy or exercise you currently do during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests a new medicine called NM8074 for people with dermatomyositis, a condition that causes muscle weakness and skin rash. The goal is to see if it can help reduce symptoms.
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
This Phase 2 trial studies whether KL1333 improves chronic fatigue and muscle weakness in adults with a confirmed mitochondrial genetic disease. You may be eligible if you have persistent fatigue for at least 3 months and signs of muscle involvement, and can safely follow study requirements.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This trial tests a new medicine, sonlicromanol, to see if it can ease chronic fatigue and improve muscle function in people with a specific genetic condition called primary mitochondrial disease. If effective, it could offer a new treatment option to improve daily energy and quality of life.
Hear when a new Polymyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.